GlassScriptPhysician profile
William Michael Mcbroom
NPI 1407998461
$3,517.95
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $359 · 2021: $477 · 2022: $715 · 2023: $439 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $637.12 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $488.21 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $471.56 | 2019-2024 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $268.11 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $180.03 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $178.01 | 2019-2024 | Farxiga, Airsupra |
| Allergan, INC. | $146.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $140.98 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $116.93 | 2019-2021 | |
| Astellas Pharma US INC | $106.21 | 2019-2023 | Myrbetriq, Veozah |
| Sunovion Pharmaceuticals INC. | $102.92 | 2019-2022 | |
| Organogenesis INC. | $98.33 | 2022 | |
| Mylan Specialty L.P. | $89.23 | 2021-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $83.12 | 2019-2021 | |
| Abbvie INC. | $79.63 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.14 | 2022 | |
| Mannkind Corporation | $41.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $41.19 | 2019-2022 | |
| Sanofi Pasteur INC. | $35.68 | 2019 | |
| Sumitomo Pharma America, INC. | $34.84 | 2023 | Gemtesa |
| Vanda Pharmaceuticals INC. | $29.72 | 2024 | Hetlioz |
| Janssen Pharmaceuticals, INC | $24.35 | 2019 | |
| Exact Sciences Corporation | $19.19 | 2023 | Cologuard Collection Kit |
| Bioventus LLC | $16.64 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.13 | 2023 | Keveyis |
| Lundbeck LLC | $13.18 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcbroom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.